Recent advances in CB1 cannabinoid receptor antagonists

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 4, 2004, Pages 498-506

  Lange, Jos H M ^a   Kruse, Chris G ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Bioisosterism; Cannabinoid CB1 receptor antagonists; Obesity; Pyrazoles; Pyrazolines; Receptor selectivity; Rimonabant

Indexed keywords

ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR 1 ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; PYRAZOLINE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG; CANNABINOID 2 RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

CHIRALITY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HEROIN DEPENDENCE; HUMAN; INSULIN RESISTANCE; MEMORY DISORDER; NONHUMAN; OBESITY; REVIEW; STEREOCHEMISTRY; ANIMAL; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG EFFECT; PHASE 3 CLINICAL TRIAL; SENSITIVITY AND SPECIFICITY; SYNTHESIS;

ANIMALS; CLINICAL TRIALS, PHASE III; HUMANS; MOLECULAR STRUCTURE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SENSITIVITY AND SPECIFICITY;

EID: 4644262320     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. 1 receptor antagonists.
2. Goya P, Jagerovic N: Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin Ther Patents (2000) 10(10):1529-1538. A review discussing CB receptor agonists and antagonists disclosed up to the year 2000.
3. Adam J, Cowley P: Recent advances in the cannabinoids. Expert Opin Ther Patents (2002) 12(10):1475-1489. An excellent review discussing CB agonists and antagonists over the period 2000 to 2002, including the diarylmethylazetidine derivatives by Aventis.
4. Palmer SL, Thakur GA, Makriyannis A: Cannabinergic ligands. Chem Phys Lipids (2002) 121(1-2):3-19. A review focusing on cannabinergic ligands and their pharmacological and therapeutic potential.
5. 1 ligands do not share a single binding site.
6. Pertwee RG: Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol (2000) 5(1):37-46.
7. De Petrocellis L, Cascio MG, Di Marzo V: The endocannabinoid system: A general view and latest additions. Br J Pharmacol (2004) 141(5):765-774. An excellent short review describing the current knowledge of the biochemistry and pharmacology of the complex endocannabinoid system.
8. 1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther (2003) 306(1):93-102.
9. Castellano C, Rossi-Arnaud C, Cestari V, Costanzi M: Cannabinoids and memory: Animal studies. Curr Drug Targets CNS Neurol Dis (2003) 2(6):389-402. A review on the effects of cannabinoids in several animal memory-related models, including knockout mice, and an overview considering studies concerning the cognitive effects of cannabinoids in humans.
10. 1 receptor antagonist improves memory in a delayed radial maze task. Eur J Pharmacol (2003) 477(3):213-217.
11. 1 receptor antagonists.
12. Mertens IL, van Gaal LF: Promising new approaches to the management of obesity. Drugs (2000) 60(1):1-9.
13. Pi-Sunyer X: A clinical view of the obesity problem. Science (2003) 299(5608):859-860.
14. 1 cannabinoid receptor-dependent modulation of feeling. J Neurosci (2002) 22(11):9612-9617.
15. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thoene-Reineke C, Ortmann S, Tomassoni F et al: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 112(3):423-431.
16. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U: Endogenous cannabinoid system as a modulator of food intake. Intern J Obes Relat Metab Disord (2003) 27(3):289-301.
17. Verty AN, McGregor IS, Mallet PE: Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett (2004) 354(3):217-220.
18. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol (2003) 284(2):R345-R353.
19. 1 receptor deleted mice. Neurosci Lett (2003) 343(3):216-218.
20. Verty AN, Singh ME, McGregor IS, Mallet PE: The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (2003) 168(3):314-323.
21. 1 receptor antagonist, SR141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (2003) 167(1):103-111.
22. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A: Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 42(4):769-776. The SAR of rimonabant analogs are provided, based on receptor binding affinities and functional antagonistic activities in both a guinea pig small intestine model and a mouse vas deferens model.
23. 1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)4-methyl-1H- pyrazole-3-carboxamide (SR141716A). J Med Chem (2002) 45(13):2708-2719.
24. 1 cannabinoid receptor. Biochem Pharmacol (2000) 60(9):1315-1323.
25. Katoch-Rouse R, Pavlova OA, Caulder T, Hoffman AF, Mukhin AG, Horti AG: Synthesis, structure-activity relationship, and evaluation of SR 141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity. J Med Chem (2003) 46(4):642-645.
26. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 46(1-3):3-26. Experimental and computational approaches for estimating solubility and permeability in discovery and development settings are described. In the discovery setting, the Lipinski's 'rule-of-5', which sets acceptable ranges for molecular weight and cLogP and limits on the number of hydrogen bond donors and acceptors, is used to predict poor absorption or permeation.
27. 1 receptor antagonists. Chem Pharm Bull (2002) 50(8):1109-1113.
28. 2 cannabinoid receptors. Bioorg Med Chem (2003) 11(2):251-263.
29. 1 cannabinoid receptor. J Pharmacol Exp Ther (2003) 306(1):363-370.
30. 1 cannabinoid receptor antagonist. Magn Reson Chem (2003) 41(4):265-268.
31. Chen X, Wang W: The use of bioisosteric groups in lead optimization. In: Annual Reports in Medicinal Chemistry. Doherty AM (Ed), Elsevier Academic Press, Amsterdam, the Netherlands (2003) 38:333-346.
32. Jagerovic N, Hernandez-Folgado L, Alkorta I, Goya P, Navarro M, Serrano A, Rodriguez de Fonseca F, Dannert MT, Alsasua A, Suardiaz M, Pascual D et al: Discovery of 5-(4-chlorophenyl)-1-(2-4-dichlorophenyl)-3-hexyl-1H-1,2,4- triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-rriazole motif. J Med Chem (2004) 47(11):2939-2942.
33. 1 receptor antagonists related to SR141716A. Bioorg Med Chem Lett (2004) 14(5):1151-1154. The first, and currently the only, SAR communication describing imidazole and triazole bioisosteres based on the diarylpyrazole derivative rimonabant.
34. 1 receptor model. Furthermore, the report provides a comparison of the crystal lattices of two structurally, closely related pyrazoline compounds having entirely different oral availabilities.
35. 1 cannabinoid receptor. J Med Chem (2002) 45(7):1447-1459.
36. 1 receptor model, based on Palczewski's crystal structure of the G-protein receptor template rhodopsin, and its interaction with rimonabant.
37. 1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction. Biopolymers (2003) 71(2):169-189.
38. Offertaler L, Fong-Ming M, Batkai S, Liu J, Begg M, Razdan RK, Martin, BR, Bukoski, RD, Kunos G: Selective ligands and cellular effectors of a G protein-coupled endothelian cannabinoid receptor. Mol Pharmacol (2003) 63(3):699-705.